Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PEPD | P12955 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30286862 | 1.00 | HTR1B (0.49) | HTR1BKDM4EHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL826152 | 0.94 | HTR1B (0.45) | HTR1BKDM4EHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL20072504 | 0.84 | HTR1B (0.46) | HTR1BKDM4EHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL2093603 | 0.84 | HTR1B (0.46) | HTR1BKDM4EHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL2607415 | 0.83 | HTR1B (0.49) | HTR1BKDM4EHSD17B10CYP2A6ALDH1A1 | |
| SCHEMBL3790878 | 0.81 | HTR1B (0.49) | HTR1BKDM4EHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL19308858 | 0.81 | HTR1B (0.42) | HTR1BKDM4EHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL25637607 | 0.80 | HTR1B (0.46) | HTR1BKDM4EHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL23075680 | 0.78 | HTR1B (0.40) | HTR1BKDM4EHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL25478994 | 0.78 | HTR1B (0.54) | HTR1BKDM4EHSD17B10CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4395500-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2024-07-03 | — | — | EP | disclosed |
| EP-4395521-A1 | CONDENSED CYCLIC COMPOUND, LIGHT-EMITTING DEVICE COMPRISING THE CONDENSED CYCLIC COMPOUND, AND ELECTRONIC APPARATUS COMPRISING THE LIGHT-EMITTING DEVICE | Samsung Display Co., Ltd. (KR) | 2024-07-03 | — | — | EP | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4306613-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS AND ELECTRONIC DEVICE INCLUDING THE LIGHT-EMITTING DEVICE | Samsung Display Co., Ltd. (KR) | 2024-01-17 | — | — | EP | disclosed |
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-12-14 | — | — | US | disclosed |
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-12-14 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230371357-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | BCP3 PTY LIMITED (AU) | 2023-11-09 | — | — | US | disclosed |
| US-7494999-B2 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC (US) | 2009-02-24 | — | — | US | disclosed |
| US-20090029971-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| WO-2007087488-A9 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | LILLY CO ELI (US) | 2008-08-28 | — | — | WO | disclosed |
| EP-1947085-A1 | Substituted indole sulfonamide compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-23 | — | — | EP | disclosed |
| US-20070270434-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070142329-A1 | Benzamide Inhibitors of the P2X7 Receptor | PFIZER INC. | 2007-06-21 | — | — | US | disclosed |
| US-7186742-B2 | Benzamide inhibitors of the P2X7 receptor | PFIZER INC (US) | 2007-03-06 | — | — | US | disclosed |
| US-20060052509-A1 | Composition containing carbon nanotubes having coating thereof and process for producing them | MITSUBISHI RAYON CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1481978-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | Mitsubishi Rayon Co., Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | HTR1B 4127/4885KDM4E 4298/4885HSD17B10 2517/4885 |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | HTR1B 746/4885KDM4E 2875/4885HSD17B10 2665/4885 |
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MPO, MUC1, CRYAB | HTR1B 2948/4885KDM4E 3937/4885HSD17B10 326/4885 |
| US-20090029971-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | HTR1B 880/4885KDM4E 3245/4885HSD17B10 485/4885 |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | PIN4, IPO5, HLCS | HTR1B 3539/4885KDM4E 2745/4885HSD17B10 2772/4885 |
| US-20230371357-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | L1CAM, CHRM1, FOXM1 | HTR1B 2137/4885KDM4E 3285/4885HSD17B10 3846/4885 |
| US-20070142329-A1 | Benzamide Inhibitors of the P2X7 Receptor | IL1R1, P2RY1, P2RX1 | HTR1B 605/4885KDM4E 4185/4885HSD17B10 4465/4885 |
| US-20070270434-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | PPARD, PPARG, PPARA | HTR1B 1441/4885KDM4E 2790/4885HSD17B10 419/4885 |
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MUC1, MPO, SERPINB1 | HTR1B 2723/4885KDM4E 3905/4885HSD17B10 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.